GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

Dawei RongYuliang WangLi LiuHengsong CaoTian HuangHanyuan LiuXiaopei HaoGuangshun SunGuoqiang SunZhiying ZhengJunwei KangYongxiang XiaZiyi ChenWeiwei TangXuehao Wang

Published in: Journal for immunotherapy of cancer (2023)

T cells exerted an effect with anti-PD1 treatment synergistically, revealing a prospective method for HCC immune therapy.

Keyphrases

randomized controlled trial
cell proliferation
mesenchymal stem cells
replacement therapy